Through the biobanking efforts of the ORIEN team and UVA's Biorepository and Tissue Research Facility (BTRF), our investigators will have access to these services:
Study Management
- Pre-screening of potential study participants
- Compliant consent of study participants
- Survey administration and phone follow-up
- Specimen coordination, processing and shipping
- Chart review/case report form completion
Clinical Data Services
- Data abstractions from EPIC to complete case report forms
- Coordinate upload of EPIC data extractions into REDCap or other data capture systems
- Queries on internal and external ORIEN databases for project feasibility
- Coordinate with Research and Clinical Trial Analytics Team and Cancer Registry for project data needs
- Feasibility for grant applications
- Feasibility for clinical trials for actual number of qualifying patients
Molecular Data Access With Clinical Data
- Access to whole exome sequencing and RNA sequencing for tumor and whole exome sequencing for germline samples
- Project-specific access to raw molecular files for UVA consented patients
- Query processed data using ORIEN informatics modules and ORIEN CBioPortal
- Project submissions for access to molecular data from other ORIEN sites
Specimen Management
Studies may either rely on the specimen management that is part of the ORIEN protocol through the ORIEN core functions or may rely on an independent protocol with consent with unique specimen criteria. For those studies that rely on the ORIEN protocol, the following table provides the collection details.
Specimens |
Tube Type |
Collection Volume |
Collection Limit |
Products |
Comments |
Blood from solid tumor patient |
K2EDTA |
10 mL |
Cumulative blood collection total of 60 mL/8wk |
1 mL whole blood stored for future germline sequencing, remainder stored as buffy coat and 1 mL plasma aliquots |
Modification to usual collection or processing generate additional charges |
Blood from blood cancer patient |
Na heparin |
20 mL |
Cumulative blood collection total of 60 mL/8wk |
Viably frozen mononuclear cell aliquots |
Modification to usual collection or processing generate additional charges |
Blood from blood cancer patient: For Circulating tumor DNA |
Streck tube |
10 mL |
Cumulative blood collection total of 60 mL/8wk | Determined on project specific basis |
Project specific basis and fees apply |
Bone marrow aspirates |
Sodium heparin |
10 mL |
10 mL/4wk |
Viably frozen mononuclear cell aliquots |
|
Buccal swabs |
MAWI DNA kit |
1 swab kit |
2 per year |
Cell suspension |
|
Lymph Node FNA Extra pass (blood cancers only) |
2 extra passes |
Snap frozen for cores, RPMI for FNA |